Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001140361-25-000467
Filing Date
2025-01-07
Accepted
2025-01-07 17:10:16
Documents
17
Period of Report
2024-10-22
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A ef20041180_8ka.htm   iXBRL 8-K/A 36055
2 EXHIBIT 23.1 ef20041180_ex23-1.htm EX-23.1 11122
3 EXHIBIT 99.1 ef20041180_ex99-1.htm EX-99.1 467504
4 EXHIBIT 99.2 ef20041180_ex99-2.htm EX-99.2 385403
5 EXHIBIT 99.3 ef20041180_ex99-3.htm EX-99.3 397387
  Complete submission text file 0001140361-25-000467.txt   1553006

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ird-20241022.xsd EX-101.SCH 3977
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20241022_lab.xml EX-101.LAB 21967
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20241022_pre.xml EX-101.PRE 16042
19 EXTRACTED XBRL INSTANCE DOCUMENT ef20041180_8ka_htm.xml XML 4218
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-34079 | Film No.: 25515664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)